PALI Research and Charts

PALI - Palisade Bio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-13 (Delayed quote data 2025-01-06)

Last 2.20	Change ⇑ +0.30 (+15.79%)	Volume 1,181,469
	Open 1.95	High 2.43	Low 1.78

8EMA (Daily) 1.88	40EMA (Daily) 2.14	50EMA (Daily) 2.27	STO (Daily) 31.808	MACD Hist (Daily) 0.144
8EMA (Weekly) 2.139	40EMA (Weekly) 2.95	50EMA (Weekly) 3.33	STO (Weekly) 15.973	MACD Hist (Weekly) -0.189


Company Profile
Palisade Bio Inc is a late-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.